IL112637A - Pharmaceutical composition containing oxybutynin and methods for the preparation thereof - Google Patents

Pharmaceutical composition containing oxybutynin and methods for the preparation thereof

Info

Publication number: IL112637A
Authority: IL; Israel
Prior art keywords: sustained release; oxybutynin; dosage form; weight; gum
Prior art date: 1994-03-04

Application number

IL11263795A

Other languages

English (en)

Other versions

IL112637A0 (en

Original Assignee

Mendell Co Inc Edward

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-04

Filing date

1995-02-14

Publication date

1999-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22766272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL112637(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-02-14 Application filed by Mendell Co Inc Edward filed Critical Mendell Co Inc Edward

1995-05-26 Publication of IL112637A0 publication Critical patent/IL112637A0/xx

1999-01-26 Publication of IL112637A publication Critical patent/IL112637A/en

Links

XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 title claims abstract description 58
229960005434 oxybutynin Drugs 0.000 title claims abstract description 58
238000000034 method Methods 0.000 title claims description 30
238000002360 preparation method Methods 0.000 title description 3
239000008194 pharmaceutical composition Substances 0.000 title description 2
238000013268 sustained release Methods 0.000 claims abstract description 69
239000012730 sustained-release form Substances 0.000 claims abstract description 69
239000000203 mixture Substances 0.000 claims abstract description 56
239000011159 matrix material Substances 0.000 claims abstract description 34
239000003349 gelling agent Substances 0.000 claims abstract description 28
238000009472 formulation Methods 0.000 claims abstract description 27
125000002091 cationic group Chemical group 0.000 claims abstract description 23
239000003431 cross linking reagent Substances 0.000 claims abstract description 23
239000008024 pharmaceutical diluent Substances 0.000 claims abstract description 4
239000007787 solid Substances 0.000 claims abstract 2
239000003826 tablet Substances 0.000 claims description 39
239000000546 pharmaceutical excipient Substances 0.000 claims description 31
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 28
239000012530 fluid Substances 0.000 claims description 23
239000000463 material Substances 0.000 claims description 19
230000002209 hydrophobic effect Effects 0.000 claims description 17
239000000230 xanthan gum Substances 0.000 claims description 17
229920001285 xanthan gum Polymers 0.000 claims description 17
235000010493 xanthan gum Nutrition 0.000 claims description 17
229940082509 xanthan gum Drugs 0.000 claims description 17
239000008184 oral solid dosage form Substances 0.000 claims description 15
230000007613 environmental effect Effects 0.000 claims description 14
229920000161 Locust bean gum Polymers 0.000 claims description 13
239000000711 locust bean gum Substances 0.000 claims description 13
235000010420 locust bean gum Nutrition 0.000 claims description 13
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 12
229920000869 Homopolysaccharide Polymers 0.000 claims description 12
239000001856 Ethyl cellulose Substances 0.000 claims description 10
238000000576 coating method Methods 0.000 claims description 10
238000004132 cross linking Methods 0.000 claims description 10
235000019325 ethyl cellulose Nutrition 0.000 claims description 10
229920001249 ethyl cellulose Polymers 0.000 claims description 10
-1 alkaline earth metal sulfates Chemical class 0.000 claims description 9
239000002552 dosage form Substances 0.000 claims description 9
239000003701 inert diluent Substances 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
239000011248 coating agent Substances 0.000 claims description 8
150000003841 chloride salts Chemical class 0.000 claims description 6
230000036571 hydration Effects 0.000 claims description 6
238000006703 hydration reaction Methods 0.000 claims description 6
239000008108 microcrystalline cellulose Substances 0.000 claims description 6
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
150000001242 acetic acid derivatives Chemical class 0.000 claims description 4
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
229910052783 alkali metal Inorganic materials 0.000 claims description 4
150000001340 alkali metals Chemical class 0.000 claims description 4
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
230000002921 anti-spasmodic effect Effects 0.000 claims description 4
150000001642 boronic acid derivatives Chemical class 0.000 claims description 4
150000003842 bromide salts Chemical class 0.000 claims description 4
150000001860 citric acid derivatives Chemical class 0.000 claims description 4
229920001577 copolymer Polymers 0.000 claims description 4
150000003893 lactate salts Chemical class 0.000 claims description 4
125000005397 methacrylic acid ester group Chemical group 0.000 claims description 4
229920013820 alkyl cellulose Polymers 0.000 claims description 3
150000002016 disaccharides Chemical class 0.000 claims description 3
150000002772 monosaccharides Chemical class 0.000 claims description 3
150000005846 sugar alcohols Polymers 0.000 claims description 3
229920001800 Shellac Polymers 0.000 claims description 2
229920002494 Zein Polymers 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
239000004208 shellac Substances 0.000 claims description 2
229940113147 shellac Drugs 0.000 claims description 2
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 2
235000013874 shellac Nutrition 0.000 claims description 2
239000007939 sustained release tablet Substances 0.000 claims description 2
239000001993 wax Substances 0.000 claims description 2
239000005019 zein Substances 0.000 claims description 2
229940093612 zein Drugs 0.000 claims description 2
239000008280 blood Substances 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
239000003814 drug Substances 0.000 description 31
239000004615 ingredient Substances 0.000 description 18
229940079593 drug Drugs 0.000 description 15
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
239000008121 dextrose Substances 0.000 description 12
238000004090 dissolution Methods 0.000 description 12
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical group CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 11
238000005469 granulation Methods 0.000 description 11
230000003179 granulation Effects 0.000 description 11
238000012545 processing Methods 0.000 description 11
229940045902 sodium stearyl fumarate Drugs 0.000 description 11
230000000694 effects Effects 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
238000013270 controlled release Methods 0.000 description 7
230000002496 gastric effect Effects 0.000 description 7
239000000499 gel Substances 0.000 description 7
238000013019 agitation Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 6
150000004676 glycans Chemical class 0.000 description 6
239000000314 lubricant Substances 0.000 description 6
229920001282 polysaccharide Polymers 0.000 description 6
239000005017 polysaccharide Substances 0.000 description 6
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
239000012467 final product Substances 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000036765 blood level Effects 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
238000007907 direct compression Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
238000005550 wet granulation Methods 0.000 description 4
229920000926 Galactomannan Polymers 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
239000008023 pharmaceutical filler Substances 0.000 description 3
210000002460 smooth muscle Anatomy 0.000 description 3
STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
ZKNJEOBYOLUGKJ-ALCCZGGFSA-N (z)-2-propylpent-2-enoic acid Chemical compound CCC\C(C(O)=O)=C\CC ZKNJEOBYOLUGKJ-ALCCZGGFSA-N 0.000 description 2
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical class C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
244000303965 Cyamopsis psoralioides Species 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007922 dissolution test Methods 0.000 description 2
229930182830 galactose Natural products 0.000 description 2
229920001600 hydrophobic polymer Polymers 0.000 description 2
239000008101 lactose Substances 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
238000011068 loading method Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229960002016 oxybutynin chloride Drugs 0.000 description 2
229920000058 polyacrylate Polymers 0.000 description 2
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
230000008569 process Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
229960001722 verapamil Drugs 0.000 description 2
TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 1
ZWJIYKCCVGLDML-UHFFFAOYSA-N 2-[2-but-1-ynyl-4-(diethylamino)phenyl]-2-cyclohexyl-2-hydroxyacetic acid;hydrochloride Chemical compound Cl.CCC#CC1=CC(N(CC)CC)=CC=C1C(O)(C(O)=O)C1CCCCC1 ZWJIYKCCVGLDML-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
206010008674 Cholinergic syndrome Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920003151 Eudragit® RL polymer Polymers 0.000 description 1
229920003152 Eudragit® RS polymer Polymers 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
206010020853 Hypertonic bladder Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
206010029279 Neurogenic bladder Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001152 anti-nicotinic effect Effects 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000003192 autonomic ganglia Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
239000001527 calcium lactate Substances 0.000 description 1
235000011086 calcium lactate Nutrition 0.000 description 1
229960002401 calcium lactate Drugs 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940099170 ditropan Drugs 0.000 description 1
239000012458 free base Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000011147 magnesium chloride Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
150000002703 mannose derivatives Chemical group 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical compound COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008019 pharmaceutical lubricant Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000011698 potassium fluoride Substances 0.000 description 1
235000003270 potassium fluoride Nutrition 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
239000011369 resultant mixture Substances 0.000 description 1
239000000344 soap Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
230000008719 thickening Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
235000019798 tripotassium phosphate Nutrition 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
239000011800 void material Substances 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL11263795A 1994-03-04 1995-02-14 Pharmaceutical composition containing oxybutynin and methods for the preparation thereof IL112637A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/206,416 US5399359A (en)	1994-03-04	1994-03-04	Controlled release oxybutynin formulations
PCT/US1994/002926 WO1995023593A1 (en)	1994-03-04	1994-03-18	Controlled release oxybutynin formulations

Publications (2)

Publication Number	Publication Date
IL112637A0 IL112637A0 (en)	1995-05-26
IL112637A true IL112637A (en)	1999-01-26

Family

ID=22766272

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11263795A IL112637A (en)	1994-03-04	1995-02-14	Pharmaceutical composition containing oxybutynin and methods for the preparation thereof

Country Status (15)

Country	Link
US (1)	US5399359A (de)
EP (1)	EP0700284B1 (de)
JP (2)	JP3699117B2 (de)
CN (1)	CN1111404C (de)
AT (1)	ATE222753T1 (de)
AU (1)	AU676556B2 (de)
CA (1)	CA2161103C (de)
DE (1)	DE69431247T2 (de)
DK (1)	DK0700284T3 (de)
ES (1)	ES2180574T3 (de)
FI (1)	FI113337B (de)
HU (1)	HUT72981A (de)
IL (1)	IL112637A (de)
PT (1)	PT700284E (de)
WO (1)	WO1995023593A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5773025A (en) *	1993-09-09	1998-06-30	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) *	1993-09-09	1995-10-03	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems for insoluble drugs
WO1996012477A1 (en) *	1994-10-21	1996-05-02	Leiras Oy	Controlled release oral delivery system containing oxybutynin
US5912268A (en) *	1995-05-22	1999-06-15	Alza Corporation	Dosage form and method for treating incontinence
US5674895A (en) *	1995-05-22	1997-10-07	Alza Corporation	Dosage form comprising oxybutynin
US6262115B1 (en)	1995-05-22	2001-07-17	Alza Coporation	Method for the management of incontinence
US6124355A (en) *	1995-05-22	2000-09-26	Guittard; George V.	Oxybutynin therapy
WO1997026865A1 (en) *	1996-01-29	1997-07-31	Edward Mendell Co., Inc.	Sustained release excipient
ES2141044B1 (es) *	1997-02-26	2001-02-01	Alza Corp	Terapia con oxibutinina.
IN186245B (de)	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
US20040062799A1 (en) *	1997-09-29	2004-04-01	Ayer Atul D.	Therapeutic composition and delivery system for administering drug
AR018321A1 (es) *	1998-03-26	2001-11-14	Alza Corp	Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US6087396A (en) *	1998-10-05	2000-07-11	Situs Corporation	Oxybutynin formulations and method of use
KR100463496B1 (ko) *	1999-09-30	2005-01-06	펜웨스트 파머슈티칼즈 컴파니	고가용성 약물용 서방성 메트리스 시스템
US7235258B1 (en)	1999-10-19	2007-06-26	Nps Pharmaceuticals, Inc.	Sustained-release formulations for treating CNS-mediated disorders
US6248359B1 (en)	2000-01-05	2001-06-19	Laboratorios Phoenix U.S.A., Inc.	Multi-tablet oxybutynin system for treating incontinence
EA008224B1 (ru) *	2001-03-13	2007-04-27	Пенвест Фармасьютикалз Ко.	Хронотерапевтические дозированные формы
US9820982B2 (en) *	2001-07-06	2017-11-21	Endo Pharmaceuticals Inc.	Oxymorphone controlled release formulations
US8329216B2 (en) *	2001-07-06	2012-12-11	Endo Pharmaceuticals Inc.	Oxymorphone controlled release formulations
CA2459976A1 (en) *	2001-09-26	2003-04-03	Penwest Pharmaceuticals Company	Opioid formulations having reduced potential for abuse
AU2002356418A1 (en) *	2001-10-08	2003-04-22	Sun Pharmaceutical Industries Limited	An antispasmodic agent spaced drug delivery system
DE10149674A1 (de)	2001-10-09	2003-04-24	Apogepha Arzneimittel Gmbh	Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US6635675B2 (en)	2001-11-05	2003-10-21	Cypress Bioscience, Inc.	Method of treating chronic fatigue syndrome
US6602911B2 (en)	2001-11-05	2003-08-05	Cypress Bioscience, Inc.	Methods of treating fibromyalgia
US20030185882A1 (en) *	2001-11-06	2003-10-02	Vergez Juan A.	Pharmaceutical compositions containing oxybutynin
US8329217B2 (en)	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
CA2494281A1 (en) *	2002-08-02	2004-02-12	Penwest Pharmaceuticals Company	Sustained release formulations of metformin
JP4884772B2 (ja) *	2003-08-04	2012-02-29	杏林製薬株式会社	経口徐放性錠剤
US20050118267A1 (en) *	2003-09-19	2005-06-02	Penwest Pharmaceuticals Co.	Chronotherapeutic dosage forms
EA200600598A1 (ru) *	2003-09-19	2006-08-25	Пенвест Фармасьютикалз Ко.	Лекарственные формы замедленного высвобождения
DK2210605T3 (en) *	2003-11-04	2017-05-22	Tcd Royalty Sub Llc	Daily single dose doses of trospium.
WO2005046663A1 (en)	2003-11-04	2005-05-26	Shire Laboratories, Inc.	Compositions of quaternary ammonium containing bioavailability enhancers
US20050287185A1 (en) *	2004-06-23	2005-12-29	David Wong	Extended release oxybutynin formulation
CN104958270A (zh) *	2004-08-25	2015-10-07	伊森舍丽斯有限公司	钾atp通道开放剂的药物制剂及其应用
DK1877219T3 (da)	2005-03-15	2011-10-03	Htc Sweden Ab	Fremgangsmåde til at vedligeholde en hård, glat gulvoverfladse omfattende et polymermateriale
US9757384B2 (en)	2005-04-06	2017-09-12	Essentialis, Inc.	Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
US7994220B2 (en) *	2005-09-28	2011-08-09	Cypress Bioscience, Inc.	Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2007059372A2 (en) *	2005-11-09	2007-05-24	St. Jude Children's Research Hospital	Use of chloroquine to treat metabolic syndrome
PL1968601T3 (pl)	2006-01-05	2012-03-30	Essentialis Inc	Sole związków otwierających kanały potasowe ATP i ich zastosowanie
US20070212414A1 (en) *	2006-03-08	2007-09-13	Penwest Pharmaceuticals Co.	Ethanol-resistant sustained release formulations
US8124598B2 (en) *	2006-09-14	2012-02-28	Sharon Sageman	7-keto DHEA for psychiatric use
US20090124650A1 (en) *	2007-06-21	2009-05-14	Endo Pharmaceuticals, Inc.	Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
JP2010532383A (ja) *	2007-07-02	2010-10-07	エッセンシャリス，インク．	カリウムａｔｐチャネル開口薬の塩およびその使用
US20100160274A1 (en) *	2007-09-07	2010-06-24	Sharon Sageman	7-KETO DHEA for Psychiatric Use
US20090076144A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched bazedoxifene
AU2009279372A1 (en)	2008-08-06	2010-02-11	Gosforth Centre (Holdings) Pty Ltd	Compositions and methods for treating psychiatric disorders
US20100160363A1 (en) *	2008-12-19	2010-06-24	Aaipharma Services Corp.	Extended-release pharmaceutical formulations
US20100159001A1 (en) *	2008-12-19	2010-06-24	Cardinal John R	Extended-Release Pharmaceutical Formulations
HUE042593T2 (hu) *	2010-03-09	2019-07-29	Alkermes Pharma Ireland Ltd	Alkoholnak ellenálló enterális gyógyszerkészítmények
US20130172411A1 (en) *	2010-03-22	2013-07-04	Cadila Healthcare Limited	Stable pharmaceutical compositions comprising fesoterodine
GB201111712D0 (en)	2011-07-08	2011-08-24	Gosforth Ct Holdings Pty Ltd	Pharmaceutical compositions
EP2819675A4 (de)	2012-02-27	2015-07-22	Essentialis Inc	Salze von kalium-atp-kanalöffnern und verwendungen davon
WO2013142482A1 (en)	2012-03-20	2013-09-26	Particle Dynamics International, Llc	Gelling agent-based dosage form
WO2015073736A1 (en)	2013-11-13	2015-05-21	Arbor Pharmaceuticals, Llc	Methods and compositions for treating adhd
JP6709226B2 (ja)	2014-11-14	2020-06-10	エッセンシャライズインコーポレイテッド	プラダー−ウィリ症候群またはスミス−マゲニス症候群を有する対象を処置するための方法
US20180362974A1 (en)	2015-07-02	2018-12-20	University Of Louisville Research Foundation, Inc.	EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
DE102015014581A1 (de) *	2015-11-12	2017-05-18	Nele Schmidt	Prolamine enthaltende Gele, Verfahren zu ihrer Herstellung und ihre Verwendung
JP2017100971A (ja) *	2015-11-30	2017-06-08	株式会社ファンケル	錠剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4303691A (en) *	1977-11-09	1981-12-01	Anderson, Clayton & Co.	Proteinaceous food product
US4309405A (en) *	1979-08-09	1982-01-05	American Home Products Corporation	Sustained release pharmaceutical compositions
JPS5630485A (en) *	1979-08-21	1981-03-27	Sansho Kk	Heat insulation composition for heating and cooling
BE902605A (fr) *	1985-06-06	1985-09-30	Therabel Res S A N V	Composition pharmaceutique utilisable dans le traitement des maladies des voies urinaires, son procede de preparation et methode d'utilisation de cette composition.
US4795642A (en) *	1986-05-01	1989-01-03	Pharmacaps, Inc.	Gelatin-encapsulated controlled-release composition
CA1272922A (en) *	1986-06-03	1990-08-21	Peter William Berry	Drug delivery device, its preparation and use
GB8628359D0 (en) *	1986-11-27	1986-12-31	Zyma Sa	Galenical formulation
US4968508A (en) *	1987-02-27	1990-11-06	Eli Lilly And Company	Sustained release matrix
DE3714074A1 (de) *	1987-04-28	1988-11-10	Hoechst Ag	Grundlage fuer schleimhaut- und prothesenhaft-pasten, verfahren zu ihrer herstellung sowie pasten auf basis dieser grundlage
US4824675A (en) *	1987-07-13	1989-04-25	Alza Corporation	Dispenser with movable matrix comprising a plurality of tiny pills
US4792452A (en) *	1987-07-28	1988-12-20	E. R. Squibb & Sons, Inc.	Controlled release formulation
SE8703881D0 (sv) *	1987-10-08	1987-10-08	Haessle Ab	New pharmaceutical preparation
US4857331A (en) *	1988-03-31	1989-08-15	Warner-Lambert Company	Sugarless pectin delivery system
US5047244A (en) *	1988-06-03	1991-09-10	Watson Laboratories, Inc.	Mucoadhesive carrier for delivery of therapeutical agent
US5169639A (en) *	1988-09-19	1992-12-08	Edward Mendell Co., Inc.	Controlled release verapamil tablets
US5135757A (en) *	1988-09-19	1992-08-04	Edward Mendell Co., Inc.	Compressible sustained release solid dosage forms
US5128143A (en) *	1988-09-19	1992-07-07	Edward Mendell Co., Inc.	Sustained release excipient and tablet formulation
US5032406A (en) *	1989-02-21	1991-07-16	Norwich Eaton Pharmaceuticals, Inc.	Dual-action tablet
US5207932A (en) *	1989-07-20	1993-05-04	Chubb National Foam, Inc.	Alcohol resistant aqueous film forming firefighting foam
US5271943A (en) *	1989-10-27	1993-12-21	Scott Health Care	Wound gel compositions containing sodium chloride and method of using them
US5215756A (en) *	1989-12-22	1993-06-01	Gole Dilip J	Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5077051A (en) *	1990-04-10	1991-12-31	Warner-Lambert Company	Sustained release of active agents from bioadhesive microcapsules
JPH04273818A (ja) *	1991-02-28	1992-09-30	Kissei Pharmaceut Co Ltd	経皮投与製剤
HU209251B (en) *	1992-03-13	1994-04-28	Synepos Ag	Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
JP3786684B2 (ja) *	1992-05-13	2006-06-14	アルザ・コーポレーション	オキシブチニンの経皮投与
JP2646170B2 (ja) *	1992-06-24	1997-08-25	日本ヘキスト・マリオン・ルセル株式会社	徐放性塩酸オキシブチニン製剤
US5330761A (en) *	1993-01-29	1994-07-19	Edward Mendell Co. Inc.	Bioadhesive tablet for non-systemic use products
US5455046A (en) *	1993-09-09	1995-10-03	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems for insoluble drugs

1994
- 1994-03-04 US US08/206,416 patent/US5399359A/en not_active Expired - Lifetime
- 1994-03-18 EP EP94913918A patent/EP0700284B1/de not_active Expired - Lifetime
- 1994-03-18 PT PT94913918T patent/PT700284E/pt unknown
- 1994-03-18 DE DE69431247T patent/DE69431247T2/de not_active Expired - Fee Related
- 1994-03-18 HU HU9503054A patent/HUT72981A/hu unknown
- 1994-03-18 JP JP52288095A patent/JP3699117B2/ja not_active Expired - Fee Related
- 1994-03-18 ES ES94913918T patent/ES2180574T3/es not_active Expired - Lifetime
- 1994-03-18 DK DK94913918T patent/DK0700284T3/da active
- 1994-03-18 AT AT94913918T patent/ATE222753T1/de not_active IP Right Cessation
- 1994-03-18 WO PCT/US1994/002926 patent/WO1995023593A1/en not_active Ceased
- 1994-03-18 AU AU65888/94A patent/AU676556B2/en not_active Ceased
- 1994-03-18 CA CA002161103A patent/CA2161103C/en not_active Expired - Fee Related
1995
- 1995-02-14 IL IL11263795A patent/IL112637A/en active IP Right Grant
- 1995-03-03 CN CN95100475A patent/CN1111404C/zh not_active Expired - Fee Related
- 1995-11-01 FI FI955215A patent/FI113337B/fi active
2004
- 2004-11-25 JP JP2004340786A patent/JP2005126444A/ja active Pending

Also Published As

Publication number	Publication date
CA2161103C (en)	1999-12-07
US5399359A (en)	1995-03-21
FI955215A0 (fi)	1995-11-01
CN1111404C (zh)	2003-06-18
ES2180574T3 (es)	2003-02-16
FI955215L (fi)	1995-11-01
JPH09501445A (ja)	1997-02-10
PT700284E (pt)	2003-01-31
IL112637A0 (en)	1995-05-26
EP0700284A4 (de)	1996-11-06
CA2161103A1 (en)	1995-09-08
ATE222753T1 (de)	2002-09-15
AU676556B2 (en)	1997-03-13
DE69431247D1 (de)	2002-10-02
DK0700284T3 (da)	2003-01-06
HU9503054D0 (en)	1996-01-29
AU6588894A (en)	1995-09-18
CN1111507A (zh)	1995-11-15
DE69431247T2 (de)	2003-01-02
JP2005126444A (ja)	2005-05-19
EP0700284A1 (de)	1996-03-13
FI113337B (fi)	2004-04-15
EP0700284B1 (de)	2002-08-28
HUT72981A (en)	1996-06-28
WO1995023593A1 (en)	1995-09-08
MX9501193A (es)	1998-07-31
JP3699117B2 (ja)	2005-09-28

Legal Events

Date	Code	Title
1999-07-14	FF	Patent granted
2000-07-26	KB	Patent renewed
2000-08-31	KB	Patent renewed
2001-06-14	KB	Patent renewed
2005-03-20	KB	Patent renewed

Publication	Publication Date	Title
US5399359A (en)	1995-03-21	Controlled release oxybutynin formulations
AU675370B2 (en)	1997-01-30	Sustained release formulations for 24 hour release of metoprolol
US5399362A (en)	1995-03-21	Once-a-day metoprolol oral dosage form
US20210008063A1 (en)	2021-01-14	Oxymorphone controlled release compositions
US5667801A (en)	1997-09-16	Sustained release heterodisperse hydrogel systems for insoluble drugs
WO2006094083A1 (en)	2006-09-08	Controlled release venlafaxine formulations
US20060105035A1 (en)	2006-05-18	Sustained release heterodisperse hydrogel systems for insoluble drugs
MXPA95001193A (es)	1998-11-09	Formulaciones de oxibutinina de liberacioncontrolada
MXPA94008792A (en)	1999-04-06	Sustained release formulations for 24 hours of metopro release
MXPA96000024A (en)	1999-01-15	Form of oral dosing of metoprolol one time
HK1071515A (en)	2005-07-22	Once-a-day metoprolol oral dosage form